Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC.CRL · Entity 3398 | EVP, Corp Strategy & Develop | August 10, 2026 | August 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Report date August 10, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,041 |
Reported balance
After 2026-08-10 transaction · row 1
1 source rowRow 1 · 2026-08-10 · Gift · Disposed 257 · Balance 31,041 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 10, 2026 Filed Aug 11, 2026 20:38 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 257 | $0.00 | $0.00 |
DisclosureSEC source: 0001100682-26-000128 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,041 Read SEC document |
| May 31, 2026 Filed Jun 2, 2026 20:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 235 | $180.71 | $42,466.85 |
DisclosureSEC source: 0001100682-26-000097 · form4.xml · nonDerivative · entry 3 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,298 Read SEC document |
| May 30, 2026 Filed Jun 2, 2026 20:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 744 | $180.71 | $134,448.24 |
DisclosureSEC source: 0001100682-26-000097 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,533 Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:40 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 5,257 | $180.71 | $949,992.47 |
DisclosureSEC source: 0001100682-26-000097 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,277 F1 · shares: Unvested restricted stock units annually ratably vest on: May 29, 2027; May 29, 2028; May 29, 2029; May 29, 2030. Read SEC document |
| May 27, 2026 Filed May 28, 2026 20:24 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 185 | $156.73 | $28,995.05 |
DisclosureSEC source: 0001100682-26-000075 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,020 Read SEC document |
| May 26, 2026 Filed May 28, 2026 20:24 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 243 | $160.30 | $38,952.90 |
DisclosureSEC source: 0001100682-26-000075 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,205 Read SEC document |
| March 03, 2026 Filed Mar 4, 2026 21:39 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | PurchaseCommon Stock | 25 | $174.54 | $4,363.50 |
DisclosureSEC source: 0001100682-26-000024 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,448 Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 21:36 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 1,749 | $211.68 | $370,228.32 |
DisclosureSEC source: 0001100682-26-000016 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,423 Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 21:36 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 5,456 | $0.00 | $0.00 |
DisclosureSEC source: 0001100682-26-000016 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,172 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 26, 2023. Read SEC document |
| August 22, 2025 Filed Jan 20, 2026 13:49 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 400 | $163.72 | $65,488.00 |
DisclosureSEC source: 0001100682-26-000002 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,716 Read SEC document |
| August 18, 2025 Filed Aug 20, 2025 20:45 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 800 | $157.60 | $126,080.00 |
DisclosureSEC source: 0001100682-25-000036 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,116 Read SEC document |
| August 07, 2025 Filed Aug 8, 2025 20:18 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 400 | $150.04 | $60,016.00 |
DisclosureSEC source: 0001127602-25-020282 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,916 Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 20:21 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 385 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-017074 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,316 Read SEC document |
| May 31, 2025 Filed Jun 3, 2025 20:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 155 | $135.63 | $21,022.65 |
DisclosureSEC source: 0001127602-25-016553 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,701 Read SEC document |
| May 30, 2025 Filed Jun 3, 2025 20:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 6,709 | $135.63 | $909,941.67 |
DisclosureSEC source: 0001127602-25-016553 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,856 F1 · shares: Unvested restricted stock units vest annually on: May 30, 2026; May 30, 2027; May 30, 2028; May 30, 2029. Read SEC document |
| May 28, 2025 Filed May 29, 2025 21:05 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 83 | $138.65 | $11,507.95 |
DisclosureSEC source: 0001127602-25-015900 · form4.xml · nonDerivative · entry 3 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,147 Read SEC document |
| May 27, 2025 Filed May 29, 2025 21:05 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 122 | $136.73 | $16,681.06 |
DisclosureSEC source: 0001127602-25-015900 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,230 Read SEC document |
| May 26, 2025 Filed May 29, 2025 21:05 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 161 | $136.73 | $22,013.53 |
DisclosureSEC source: 0001127602-25-015900 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,352 Read SEC document |
| May 13, 2025 Filed May 15, 2025 20:38 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 500 | $145.41 | $72,705.00 |
DisclosureSEC source: 0001127602-25-014484 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,513 Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 21:36 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 4,400 | $162.50 | $715,000.00 |
DisclosureSEC source: 0001127602-25-006249 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,013 Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 846 | $165.57 | $140,072.22 |
DisclosureSEC source: 0001127602-25-002780 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,413 Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 21:58 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 2,738 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-25-002780 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,259 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 27, 2022. Read SEC document |
| August 08, 2024 Filed Aug 12, 2024 20:13 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,780 | $199.36 | $354,860.80 |
DisclosureSEC source: 0001127602-24-022003 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,521 Read SEC document |
| June 03, 2024 Filed Jun 4, 2024 20:46 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GiftCommon Stock | 311 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-017714 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,301 Read SEC document |
| May 31, 2024 Filed Jun 3, 2024 20:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 4,797 | $208.44 Strike: $208.44 | $999,886.68 |
DisclosureSEC source: 0001127602-24-017309 · form4.xml · derivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,797 Underlying: Common Stock · 4,797 shares Expires 2034-05-31 F2 · shares: Stock options vest as follows: 1,199 on May 31, 2025, 1,199 on May 31, 2026, 1,199 on May 31, 2027, and 1,200 on May 31, 2028. Read SEC document |
| May 31, 2024 Filed Jun 3, 2024 20:37 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 2,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-017309 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,612 F1 · shares: Unvested restricted stock units vest as follows: 527 on May 31, 2025, 528 on May 31, 2026, 528 on May 31, 2027, and 528 on May 31, 2028. Read SEC document |
| May 29, 2024 Filed May 31, 2024 20:19 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 223 | $214.51 | $47,835.73 |
DisclosureSEC source: 0001127602-24-017116 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,501 Read SEC document |
| May 28, 2024 Filed May 28, 2024 21:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 125 | $217.21 | $27,151.25 |
DisclosureSEC source: 0001127602-24-016726 · form4.xml · nonDerivative · entry 3 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,724 Read SEC document |
| May 27, 2024 Filed May 28, 2024 21:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 184 | $217.21 | $39,966.64 |
DisclosureSEC source: 0001127602-24-016726 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,849 Read SEC document |
| May 26, 2024 Filed May 28, 2024 21:29 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 243 | $217.21 | $52,782.03 |
DisclosureSEC source: 0001127602-24-016726 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,033 Read SEC document |
| May 10, 2024 Filed May 14, 2024 20:49 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,304 | $226.97 | $295,968.88 |
DisclosureSEC source: 0001127602-24-015276 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,276 Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 22:20 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 838 | $238.93 | $200,223.34 |
DisclosureSEC source: 0001127602-24-005818 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,620 Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:28 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 1,025 | $220.28 | $225,787.00 |
DisclosureSEC source: 0001127602-24-002802 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,458 Read SEC document |
| January 29, 2024 Filed Jan 31, 2024 22:28 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 3,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-002802 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,483 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 28, 2021. Read SEC document |
| January 29, 2024 Filed Mar 25, 2024 21:55 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 994 | $220.28 | $218,958.32 |
DisclosureSEC source: 0001127602-24-011098 · form4a.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,418 Read SEC document |
| January 29, 2024 Filed Mar 25, 2024 21:55 UTC Amendment | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 3,279 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-011098 · form4a.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,412 F1 · shares: Reflects shares of common stock issued following the achievement of performance goals set forth in performance share unit awards originally granted on May 28, 2021. Read SEC document |
| November 30, 2023 Filed Dec 1, 2023 21:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 1,850 | $197.73 | $365,800.50 |
DisclosureSEC source: 0001127602-23-028591 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,133 Read SEC document |
| November 09, 2023 Filed Nov 13, 2023 21:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionStock Options (Right to Buy) · Derivative | 9,128 | $0.00 Strike: $144.67 | $0.00 |
DisclosureSEC source: 0001127602-23-027226 · form4.xml · derivative · entry 4 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,128 shares Expires 2024-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2023 Filed Nov 13, 2023 21:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 6,543 | $173.76 | $1,136,911.68 |
DisclosureSEC source: 0001127602-23-027226 · form4.xml · nonDerivative · entry 3 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,983 F2 · price: This transaction was executed in multiple trades at prices ranging from $173.74 to $174.16. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 09, 2023 Filed Nov 13, 2023 21:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 2,585 | $172.77 | $446,610.45 |
DisclosureSEC source: 0001127602-23-027226 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,526 F1 · price: This transaction was executed in multiple trades at prices ranging from $172.32 to $173.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 09, 2023 Filed Nov 13, 2023 21:12 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Exercise / conversionCommon Stock | 9,128 | $144.67 | $1,320,547.76 |
DisclosureSEC source: 0001127602-23-027226 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,111 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 10, 2023 Filed Aug 14, 2023 20:11 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 700 | $216.52 | $151,564.00 |
DisclosureSEC source: 0001127602-23-022480 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,983 Read SEC document |
| May 29, 2023 Filed May 31, 2023 22:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 223 | $194.12 | $43,288.76 |
DisclosureSEC source: 0001127602-23-017254 · form4.xml · nonDerivative · entry 4 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,683 Read SEC document |
| May 28, 2023 Filed May 31, 2023 22:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 125 | $194.12 | $24,265.00 |
DisclosureSEC source: 0001127602-23-017254 · form4.xml · nonDerivative · entry 3 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,906 Read SEC document |
| May 27, 2023 Filed May 31, 2023 22:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | Tax withholdingCommon Stock | 184 | $194.12 | $35,718.08 |
DisclosureSEC source: 0001127602-23-017254 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,031 Read SEC document |
| May 26, 2023 Filed May 31, 2023 22:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantStock Options (Right to Buy) · Derivative | 5,252 | $194.12 Strike: $194.12 | $1,019,518.24 |
DisclosureSEC source: 0001127602-23-017254 · form4.xml · derivative · entry 5 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,252 Underlying: Common Stock · 5,252 shares Expires 2033-05-26 F2 · shares: Stock Options vest as follows: 1,313 on May 26, 2024, 1,313 on May 26, 2025, 1,313 on May 26, 2026 and 1,313 on May 26, 2027. Read SEC document |
| May 26, 2023 Filed May 31, 2023 22:10 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | GrantCommon Stock | 2,189 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-017254 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,215 F1 · shares: Restricted Stock Units vest as follows: 547 on May 26, 2024, 547 on May 26, 2025, 547 on May 26, 2026 and 548 on May 26, 2027. Read SEC document |
| May 15, 2023 Filed May 16, 2023 18:18 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 345 | $190.39 | $65,684.55 |
DisclosureSEC source: 0001127602-23-015694 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,026 Read SEC document |
| May 12, 2023 Filed May 15, 2023 18:49 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 9 | $194.07 | $1,746.63 |
DisclosureSEC source: 0001127602-23-015525 · form4.xml · nonDerivative · entry 2 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,371 Read SEC document |
| May 12, 2023 Filed May 15, 2023 18:49 UTC | CHARLES RIVER LABORATORIES INTERNATIONAL, INC. CRL · Entity 3398 | SaleCommon Stock | 950 | $193.02 | $183,369.00 |
DisclosureSEC source: 0001127602-23-015525 · form4.xml · nonDerivative · entry 1 LaPlume Joseph W · CIK 0001767215 · EVP, Corp Strategy & Develop 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,380 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.